



Measurement and valuation of productivity in health economic evaluations


Perspectives, methods and challenges

PRM49

Claudio Schiener (WifOR GmbH), Sarah Hofmann (WifOR GmbH), Malina Müller (WifOR GmbH)


Background, objectives & methods

- Productivity costs are “costs associated with production loss and replacement costs due to illness, disability and death of persons both paid and unpaid” [1].
- Differences in economic evaluations & cost of illness studies concerning pharmacoeconomic guidelines, study perspective & valuation [2].
- Study objective: Identify, analyze, categorize and compare existing methodologies and upcoming challenges of measuring productivity.




Results: Overview over methodological aspects

Methodological aspects in health economic evaluation



Results : Methodological categorization of identified studies



Conclusion & future challenges

Conclusions

- This study summarizes methodological aspects concerning the inclusion of productivity costs used in current health economic studies
- Most study apply human capital method for monetarization of lost absenteeism (presenteeism), despite broad critique in the literature
- Heterogeneous wage estimates: reported wages → GDP/capita
- Results are (partly) incomparable between countries and diseases
➔ International standardized pharmacoeconomic guidelines needed [4]

Future challenges

- Standardization of pharmacoeconomic guidelines
- Renunciation of the assumption of 1:1 productivity losses (multiplier & compensation effects) & precise estimations (and regular updating) of the friction period differentiated by countries, industries etc. [3]
- Greater consideration of presenteeism and unpaid work especially for treatments of elderly [4] and methodologies of including unpaid labor [3]
- Comparison of employee vs. employer productivity estimates [5]
- Including family spillover effects [6]
- Determining the feasibility of including presenteeism intensity

References

- [1] Brouwer et al. (1997). Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion. *Health Economics*, 6(5), 511 – 514
- [2] Knies et al. (2010). The Transferability of Valuing Lost Productivity across Jurisdictions. Differences between National Pharmacoeconomic Guidelines. *Value in Health*, 13(5), 519 – 527.
- [3] Krol & Brouwer (2014). How to Estimate Productivity Costs in Economic Evaluations. *Pharmacoeconomics*, 32, 335 – 344
- [4] Huter et al. (2018). Economic evaluation of health promotion interventions for older people: do applied economic studies meet the methodological challenges?
- [5] Kigozi et al. (2017). The Estimation and Inclusion of Presenteeism Costs in Applied Economic Evaluation: A Systematic Review. *Value in Health* 20(3), 496 – 506
- [6] Al-Janabi et al. (2016). A Framework for Including Family Health Spillovers in Economic Evaluation. *Medical Decision Making*, 36(2), 176 – 186
- [7] Gold, MR et al. (1996). *Cost-Effectiveness in Health and Medicine*. Oxford: Oxford University Press
- [8] Swiebel J. (1994). *Towards a Broader Perspective of Work and Employment*. Discussion Paper of the United Nations Department of Economic and Social Affairs 1999/4



Contact:
claudio.schiener@wifor.com
sarah.hofmann@wifor.com
malina.mueller@wifor.com
wifor.com